



ORIGINAL ARTICLE

Aortic valve replacement for severe aortic stenosis in octogenarians: Patient outcomes and comparison of operative risk scores



António Tralhão^{a,*}, Rui Campante Teles^a, Manuel Sousa Almeida^a, Sérgio Madeira^a, Miguel Borges Santos^a, Maria João Andrade^a, Miguel Mendes^a, José Pedro Neves^b

^a Hospital de Santa Cruz, Western Lisbon Hospital Centre, Department of Cardiology, Carnaxide, Portugal

^b Hospital de Santa Cruz, Western Lisbon Hospital Centre, Department of Cardiothoracic Surgery, Carnaxide, Portugal

Received 14 September 2014; accepted 2 January 2015

Available online 8 July 2015

KEYWORDS

Aortic valve surgery;
Aortic stenosis;
Octogenarians;
Risk assessment;
EuroSCORE;
STS score

Abstract

Introduction and Aim: Isolated aortic valve replacement (AVR) in octogenarians is associated with increased operative risk, due to higher prevalence of associated risk factors and other comorbidities, making outcome prediction essential. We sought to analyze operative mortality and morbidity and to compare the predictive accuracy of the logistic European System for Cardiac Operative Risk Evaluation score (EuroSCORE) I, EuroSCORE II and Society of Thoracic Surgeons (STS) score in this population.

Methods: We retrospectively enrolled 106 consecutive octogenarians with symptomatic severe aortic stenosis undergoing isolated AVR in a large-volume single center between January 2003 and December 2010 and calculated surgical risk scores.

Results: Mean logistic EuroSCORE I, EuroSCORE II and STS score were 14.6 ± 11 , 4.4 ± 3.1 and $4.0 \pm 2.4\%$, respectively. Mean operative mortality was 5.7% (six patients). Two (1.9%) patients suffered an ischemic stroke, three (2.8%) required temporary hemodialysis and five (4.7%) had a permanent pacemaker implanted. Five (4.7%) required rethoracotomy. No myocardial infarction or sternal wound infection was observed. Calibration-in-the-large showed overestimation of operative mortality with logistic EuroSCORE I ($p=0.036$), whereas EuroSCORE II ($p=1.0$) and STS ($p=1.0$) showed good calibration. C-statistic values were 0.877 (95% CI 0.800–0.933) for logistic EuroSCORE I, 0.792 (95% CI 0.702–0.864) for EuroSCORE II and 0.702 (95% CI 0.605–0.787) for STS, without statistically significant differences.

* Corresponding author.

E-mail address: atralhao@gmail.com (A. Tralhão).

PALAVRAS-CHAVE

Cirurgia valvular aórtica;
 Estenose aórtica;
 Octogenários;
 Avaliação do risco;
 EuroSCORE;
 STS score

Conclusions: These results suggest that AVR can be performed safely in selected octogenarians. EuroSCORE II and STS demonstrated superior calibration and should be the preferred tools for risk assessment, at least for this population.

Published by Elsevier España, S.L.U. on behalf of Sociedade Portuguesa de Cardiologia.

Cirurgia valvular aórtica em octogenários com estenose aórtica grave: resultados operatórios e comparação de scores de risco

Resumo

Introdução e objetivos: A cirurgia de substituição valvular aórtica (SVA) envolve um risco acrescido em octogenários, pela elevada prevalência de fatores de risco e comorbidades, tornando essencial a predição de resultados. Pretendemos analisar a mortalidade operatória e comparar as capacidades preditivas do *European System for Cardiac Operative Mortality* (EuroSCORE) I, EuroSCORE II e o *Society of Thoracic Surgeons* (STS) *score* nesta população.

Métodos: Analisámos retrospectivamente 106 octogenários com estenose aórtica grave sintomática, submetidos a SVA isolada num centro terciário, entre janeiro de 2003 e dezembro de 2010.

Resultados: O EuroSCORE I logístico, o EuroSCORE II e o STS *score* médios foram $14,6 \pm 11,4, 4,4 \pm 3,1$ e $4,0 \pm 2,4\%$, respetivamente. A mortalidade operatória foi 5,7% (seis doentes). Registámos como complicações dois (1,9%) acidentes vasculares cerebrais isquémicos, hemodíalise transitória em três doentes (2,8%) e cinco (4,7%) implantes de *pacemaker* definitivo. Cinco doentes (4,7%) requereram revisão da hemostase. Não se verificaram enfarte agudo do miocárdio ou infeção do esterno. O EuroSCORE I logístico sobreestimou a mortalidade ($p=0,036$), enquanto o EuroSCORE II ($p=1,0$) e o STS ($p=1,0$) *score* mostraram boa calibração. A area sob a curva foi de 0,877 (CI 95% 0,800-0,933) para o EuroSCORE I logístico, 0,792 (CI 95% 0,702-0,864) para o EuroSCORE II e 0,702 (CI 95% 0,605-0,787) para o STS *score* ($p=ns$ para comparações).

Conclusões: Estes resultados sugerem que a SVA pode ser realizada com morbi-mortalidade aceitável em octogenários selecionados. O EuroSCORE II e o STS *score* demonstraram melhor calibração e devem ser as métricas preferidas na avaliação do risco operatório desta população. Publicado por Elsevier España, S.L.U. em nome da Sociedade Portuguesa de Cardiologia.

Introduction

Degenerative calcific aortic valve stenosis (AS) is the second most common valvular lesion in western countries, accounting for almost a third of native valve disease.^{1,2} Due to its degenerative etiology, the number of affected individuals rises sharply with age, reaching around 8.1% at the age of 85.³ The burden of AS is further heightened by increased longevity, meaning more elderly patients are expected to require therapeutic intervention in the future.^{4,5} Once severe AS becomes symptomatic, the natural course of the disease leads to a poor short-term prognosis, with only 25% survival at three years if left untreated.^{3,4} In the light of these findings, aortic valve replacement (AVR) is currently the recommended treatment (class I, level of evidence B) for severe symptomatic AS, in both European and American guidelines.^{6,7}

Currently, surgical AVR and, more recently, transcatheter aortic valve implantation (TAVI) are the only treatment options that have an impact on survival.^{6,8} A larger body of experience supports AVR as the reference treatment,

with TAVI being reserved for patients unsuitable for AVR due to a high risk profile or inoperability.⁸ However, the precise operative risk cutoff figure above which AVR surgery should be withheld in a particular patient (for which age is often used as a surrogate) remains a matter of ongoing debate. Hence, there is a need to describe contemporary outcomes of conventional AVR as the population ages and transcatheter options become available. In recent decades, cardiac surgery has been performed with increased safety. Several series have consistently reported progressively lower operative mortality, ranging from 3.9% to 9%, in octogenarians undergoing AVR.⁹⁻¹⁶ Medium- and long-term survival after AVR surgery has also improved, paralleling age-matched healthy individuals.^{9,17}

In this regard, operative mortality scores can play a role in improving the identification of the subset of elderly patients who could be candidates for conventional surgery. The 2003 logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) I has gained widespread popularity as a screening tool.¹⁸ However, it has shown a tendency to overestimate mortality in contemporary surgical series

of elective AVR patients.¹⁹ To overcome this limitation, an updated version (EuroSCORE II) was built that further refined the model variables, which could ultimately translate into better calibration and discriminative power.²⁰ Overseas, the American counterpart of EuroSCORE II, the Society of Thoracic Surgeons (STS) score, has also been validated in a large cohort of patients and may be used as an alternative.²¹ However, controversy remains about the predictive accuracy of these scores in the elderly and their relative performance. We sought to assess the operative mortality of octogenarians undergoing isolated AVR and to compare the performance of the new EuroSCORE II against logistic EuroSCORE I and the STS score in predicting mortality outcomes in this population.

Methods

Between June 2003 and November 2010, 106 consecutive octogenarians with symptomatic severe AS underwent isolated AVR as their first surgical cardiac intervention in a high-volume center and were included in this study. Aortic valve disease severity was graded according to the European Society of Cardiology (ESC) guidelines on valvular heart disease.⁶ All patients underwent comprehensive transthoracic Doppler echocardiographic assessment at the institution's core laboratory.

Significant obstructive coronary artery disease requiring concomitant coronary artery bypass grafting (CABG) was excluded by coronary angiography. Patients with associated valvular lesions requiring intervention were also excluded from the study. All operations were performed using a standard approach, with a median sternotomy, the application of extracorporeal circulation and cold blood cardioplegia. Choice of type and size of valve prosthesis was left to the surgeon's discretion.

Operative mortality was defined as death occurring within 30 days of surgery or during the index admission. Logistic EuroSCORE I, II and STS score were computed using the respective online calculators, from data retrospectively retrieved from patients' medical records. Since data on 'poor mobility' were missing for a substantial proportion of patients, EuroSCORE II was calculated without this variable; an analysis by Barili et al. showed that omitting this variable did not reduce the discriminative accuracy of EuroSCORE II.¹⁸ Post-operative complications were defined as myocardial infarction (MI), stroke, need for hemodialysis, atrioventricular block requiring permanent pacemaker implantation, sternal wound infection and redo thoracotomy for bleeding. Variable and outcome data were collected retrospectively from patients' medical records.

Continuous variables are reported as mean \pm standard deviation or median (interquartile range [IQR]). Categorical variables are reported as proportions (%). Due to the small population size, calibration-in-the-large was performed using the chi-square test (two-sided), with a significant p-value indicating reduced calibration. The discriminative power of each score was assessed using receiver operating characteristic (ROC) curve analysis and C-statistics for a 95% confidence level. A value of 0.5 signifies absence of discriminative power, while a value of 1 signifies a perfect

result. ROC curves were compared using the method proposed by DeLong et al., in which a non-significant p means equal discriminative power (95% confidence level).²² Statistical Package for the Social Sciences™ version 21.0 (IBM SPSS Modeler, Chicago, IL) and Medcalc™ version 6.0 (MedCalc Software, Ostend, Belgium) were used for data processing and statistical analysis.

Results

Preoperative variables

Patients' mean age was 83.0 ± 2.1 years and 39 (36.8%) were male (Table 1). The surgical procedure was performed electively in 96 patients (90.1%) and as an urgent intervention in the other 10 (9.9%). Twenty-four patients (22.6%) had left ventricular ejection fraction (LVEF) $<50\%$, 37 (34.9%) were in NYHA class III or IV, 39 (36.8%) had angina, 16 (15.1%) had extracardiac arteriopathy and 18 (17.0%) presented creatinine clearance <30 ml/min/m².

Perioperative variables

A bioprosthetic valve was implanted in all patients (Table 2); Mitroflow™ was the most widely used model (66%). The most used ring size was 21 mm, with a median of 21 (19 mm: 14 cases; 21 mm: 49 cases; 23 mm: 40 cases; 25 mm: 3 cases).

Median mechanical ventilation time was 10 h (IQR 8–14 h), median intensive care unit stay was 24 h (IQR 14–60 h) and median hospital stay was 9 days (IQR 9–12 days).

Operative mortality, surgical risk scores and post-operative complications

Operative mortality occurred in six patients (5.7%). Causes of death were heart failure in three cases (pump failure in two patients, patient-prosthesis mismatch in one), suspected aortic rupture in one, sepsis in one and pneumonia in one.

Mean logistic EuroSCORE I, EuroSCORE II and STS score were $14.6 \pm 11\%$, $4.4 \pm 3.1\%$ and $4.0 \pm 2.4\%$, respectively (Table 3 and Figure 1). Calibration-in-the-large showed




Figure 1 Operative risk score calibration-in-the-large.

Table 1 Pre-operative variables.

Age (years)	83.1±2.2
Male (%)	39
Height (m)	1.59±0.1
Weight (kg)	67.4±13
BMI (kg/m ²)	26.5±4.4
Smoking (current or past) (%)	11
Hypertension (%)	81
Diabetes (%)	20
Dyslipidemia	68
Previous MI	10
Previous PCI	8
Previous cardiac surgery	2
Creatinine clearance (ml/min/m ²)	
≥60	28
30–59	60
<30	18
LVEF	
Normal	86
30–45%	18
<30%	3
PASP ≥55 mmHg	6
NYHA class	
I	27
II	43
III	31
IV	6
Angina	39
CCS class IV angina	0
Chronic pulmonary disease	8
Extracardiac arteriopathy	16
Neurological dysfunction	4
AVR timing	
Elective	96
Urgent	10
Emergent or salvage	0
Active endocarditis	1
Cardiogenic shock	0
Intra-aortic balloon pump	0

AVR: aortic valve replacement; BMI: body mass index; CCS: Canadian Cardiovascular Society; LVEF: left ventricular ejection fraction; MI: myocardial infarction; NYHA: New York Heart Association; PASP: pulmonary artery systolic pressure; PCI: percutaneous coronary intervention.

overestimation of operative mortality with logistic EuroSCORE I (14.6 vs. 5.6%, $p=0.036$), whereas EuroSCORE II (4.4 vs. 5.6%, $p=1.0$) and STS score (4.0 vs. 5.7%, $p=1.0$) exhibited similar mean values, closer to the observed mortality.

ROC curve analysis (Figure 2) yielded significant C-statistic values of 0.877 (95% CI 0.800–0.933) for logistic EuroSCORE I, 0.792 (95% CI 0.702–0.864) for EuroSCORE II and 0.702 (95% CI 0.605–0.787) for STS score. Comparison of ROC curves using the DeLong method was not significant for differences in discriminative power (Table 3).

Table 2 Operative variables.

Type of prosthetic valve implanted	
Biologic	106
Carpentier-Edwards Perimount™ (%)	9
Carpentier-Edwards Perimount Magna™ (%)	2
Mitroflow™ (%)	70
Mosaic Ultra™ (%)	9
St. Jude Epic™ (%)	14
St. Jude Trifecta™ (%)	2
Prosthesis ring size (median, mm)	21
Duration of ICU stay (median, h)	24
Hospital stay (median, days)	9

ICU: intensive care unit.

Non-fatal complications occurred in fifteen patients (14.2%). Two (1.9%) suffered an ischemic stroke (one with full recovery, one with mild residual hemiparesis), three (2.8%) required temporary hemodialysis and five (4.7%) had a permanent pacemaker implanted due to complete atrio-ventricular block. No MI or sternal wound infection was observed. Five (4.7%) patients required repeat thoracotomy due to hemodynamic instability or suspected ongoing blood loss.

Discussion

The present study aimed to assess up-to-date figures concerning operative mortality for isolated AVR in the geriatric population and to compare the performance of three commonly used risk calculation tools to predict operative outcomes.

Operative results

In this series of octogenarians undergoing isolated AVR for severe symptomatic AS in a single center, operative mortality was 5.6%. In a population generally regarded as high-risk, we consider this figure acceptable.

Elayda et al. published one of the first surgical series, reporting a mortality of 5.3% in 77 patients aged 80 or over undergoing AVR, between 1975 and 1991.²³ The authors found LVEF <45% to be an independent predictor of mortality, together with hypertension and associated CABG. Since then, the number of published surgical series and observational studies has increased modestly, but not without some discrepancies (Table 4). Gehlot et al. described an operative mortality of 13% in 322 octogenarians, of whom 43% had concomitant CABG and 56% were urgent or emergent procedures, both of them independent predictors of operative mortality.¹⁴ The presence of coronary artery disease requiring CABG and clinical instability are two recognized factors that can contribute to increased operative mortality, by 2- and 4–13-fold, respectively.²⁴ Taken together, these two studies seem to suggest a lower risk associated with isolated elective AVR surgery in octogenarians. However, two other surgical series show higher than average mortality rates. Bloomstein et al. reported mortality of 16.7% in 180 septuagenarians and octogenarians undergoing isolated AVR surgery. In this series, a valve size of 19 mm

Table 3 Operative risk score analysis.

	Mean ± SD	Minimum	Maximum	Calibration-in-the-large	C-statistic	p
Logistic EuroSCORE I	14.6 ± 11	5.8	64.3	p=0.036	0.877 (95% CI: 0.800–0.933)	0.001
EuroSCORE II	4.4 ± 3.1	1.5	17.0	p=1.0	0.792 (95% CI: 0.702–0.864)	0.009
STS score	4.0 ± 2.4	2.3	17.6	p=1.0	0.702 (95% CI: 0.605–0.787)	0.090

CI: confidence interval; SD: standard deviation; STS: Society of Thoracic Surgeons.




Figure 2 Distribution and receiver operating characteristic curves for logistic EuroSCORE I (a), EuroSCORE II (b) and STS score (c).

Table 4 Examples of literature series of surgical AVR in elderly patients.

Author	Year	Mean age	No. of patients	Operative mortality (%)	Comments
Elayda et al. ²³	1993	82.6	77	5.7	27% mortality with additional surgical procedures
Gehlot et al. ¹⁴	1996	82.7	322	13.0	56% urgent or emergent procedures, 43% concomitant CABG
Bloomstein et al. ²⁵	2001	76	180	16.7	23.8% mortality with body surface area <1.8 m ²
Mistiaen et al. ³⁵	2001	73	400	3.8	Previous CABG did not influence mortality
Kohl et al. ⁹	2007	82.8	162	9.0	32% mortality for urgent procedures
Leontyev et al. ²⁶	2009	82.7	282	10.8	EuroSCORE I imprecise for perioperative mortality discrimination
Ferrari et al. ³⁶	2010	82.2	124	5.6	Very similar results to present study
Litmathe et al. ¹⁰	2011	82.7	304	5.8	50% mechanical valves
Dell'Amore et al. ¹¹	2012	82.0	188	4.3	No mortality difference between AVR and AVR+CABG patients
Di Eusanio et al. ¹²	2012	82.1	638	4.5	One of the largest literature series
Saxena et al. ¹⁵	2012	83.4	531	4.0	One of the lowest mortality results
Total		81.1^a	3208	6.8^a	

AVR: aortic valve replacement; CABG: coronary artery bypass grafting.

^a Mean value.

was associated with significantly increased mortality (26.1% in 66 patients with 19 mm valve vs. 20% in 55 patients with 21 mm valve vs. 23% in 64 patients with 23–29 mm valve, $p=0.017$). Moreover, there was a strong correlation between small body surface area, small valve size, and female gender.²⁵ In a series by Leontyev et al., operative mortality was also distinctly higher (10.8%) than in other studies. These authors included patients with low (logistic EuroSCORE I $\leq 10\%$), intermediate (10–20%) and high ($\geq 20\%$) operative risk. However, in the 102 low-risk patients, operative mortality was 7.2%.²⁶ More recently, Di Eusano et al. reported 4.5% operative mortality in a large regional series of 638 octogenarians undergoing isolated AVR surgery, with a mean logistic EuroSCORE I of 13.0 ± 7.9 , very similar to our results.¹² In another large series, Saxena et al. reported a 4.0% 30-day mortality rate in 531 octogenarians undergoing isolated AVR surgery. Although no formal surgical risk score calculation was mentioned, precluding a more accurate comparison, these results are also in agreement with the present series.¹⁵

Understandably, naturally diminished global physiological and organ reserve makes this population more vulnerable to operative complications. Nevertheless, in the present series we observed a low rate of complications in isolated AVR, similar to those reported in the recent series by Di Eusano et al. (1.3% for stroke, 0.3% for MI, 4.4% for complete atrioventricular block and 3.7% for redo thoracotomy).¹²

Comparison of operative risk scores

All scores showed good discriminative power in our series, but the logistic EuroSCORE I overestimated mortality by almost three times the observed value. Previous studies have demonstrated a systematic exaggeration of operative mortality by a factor of two to three.^{19,20,27–30} As EuroSCORE was originally devised in 1995, a large part of this discrepancy can probably be attributed to natural improvements in surgical techniques and post-operative patient management, and changes in population case mix and outcomes in recent years.^{12,31} By contrast, both EuroSCORE II and STS score showed excellent calibration.

Nevertheless, the logistic EuroSCORE I showed good discriminative power, which was not statistically different from EuroSCORE II or STS score, so ultimately no particular score was favored. Barili et al. also found this lack of added value when using ROC curves to compare the two versions of EuroSCORE in general cardiac surgery.¹⁸ In another study by the same authors, the STS score showed a slightly higher C-statistic, but again without statistically significant difference.²⁹

Still, theoretical and methodological concerns have been voiced regarding calibration of EuroSCORE II, particularly regarding the validity of the Hosmer-Lemeshow test for this purpose. Barili et al. set out to answer such concerns in a recent study including more than 12 000 patients undergoing cardiac surgery.¹⁸ The authors employed four different methods to assess calibration (including the use of calibration curves) and demonstrated that EuroSCORE II has an optimal calibration performance until 30% actual mortality, beyond which it progressively overestimates mortality. On the basis of these findings, EuroSCORE II could be considered

an appropriate tool to assess operative risk in the general octogenarian population, including our study cohort. However, in a truly high-risk population, such lack of calibration can be crucial, particularly when considering transcatheter therapy.

Our findings appear to suggest that EuroSCORE II should be the preferred tool for estimation of operative risk mortality in octogenarians undergoing isolated AVR surgery. The STS score, although equally well calibrated, has the potential disadvantages of being derived from an American cohort and being more cumbersome and time-consuming due to a larger set of variables.

More than a decade after the introduction of TAVI for the treatment of severe AS, should age be a decisive factor in the decision whether to deny AVR surgery? Naturally, age per se, or as a surrogate of an increased prevalence of operative risk factors, is always present in all risk scores. An analysis by lung et al. showed that low LVEF and greater age were significantly associated with the decision to deny surgery to 72 out of 216 patients with severe AS aged ≥ 75 .³² Neurological dysfunction was the only comorbidity significantly linked with the decision not to operate, which seems to suggest that age itself, rather than associated comorbidities, is used as a true criterion more than a surrogate marker to assess a patient's pre-operative physiological status. Still, issues related to quality of life in the very old, which are inherently subjective and difficult to evaluate, should also be considered when deciding on the potential benefit of AVR.

Our patient cohort, although limited in size and inevitably suffering the limitations and biases of a single-center analysis, contributes to the growing evidence that isolated AVR surgery can indeed be performed with acceptable results in selected octogenarians. Furthermore, current age boundaries are progressively being challenged. Yerebakan et al. reported 7.6% overall operative mortality in a cohort of 119 nonagenarian patients, of whom 66 underwent isolated AVR.³³

Proper patient selection has a decisive role in achieving good operative results. A number of conditions such as LVEF $< 30\%$, severe renal failure, severe lung disease, emergent surgery and simultaneous CABG have been identified as markers of poor outcome. Each of these variables, when added to age as the sole variable contributing to increased operative risk, may advise against AVR, not only because of the expected high operative mortality but also due to the reduced long-term benefit of the intervention.^{6,24}

In an increasingly aging population, the number of patients who need a therapeutic intervention will continue to grow. From these results, and given the advent of TAVI and the data from the PARTNER trial, the question arises of what is the best treatment option.^{8,34} The answer can be found by an objective assessment of each case, and for the most difficult and doubtful cases, a multidisciplinary evaluation by the "heart team" would be desirable to find the best option for the patient. In this regard, the development of a new, integrated score, perhaps including variables such as frailty, could help to define the best treatment strategy for each individual case, similar to what the SYNTAX II score did for revascularization in coronary artery disease. Further studies are needed to confirm the feasibility of this strategy.

Conclusions

This study adds to the evidence gathered so far on the safety of isolated AVR in elderly patients, in both morbidity and mortality outcomes. However, further studies are needed to better assess the applicability of these results to patients at increased risk.

EuroSCORE II and the STS score should be the preferred operative risk assessment instruments, offering an important contribution to contemporary clinical decision-making in selected octogenarians with severe symptomatic AS.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult. *Nat Rev Cardiol*. 2011;8:162–72.
2. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. *Lancet*. 2006;368:1005–11.
3. Iung B, Vahanian A. Degenerative calcific aortic stenosis: a natural history. *Heart (British Cardiac Society)*. 2012;98 Suppl. 4:iv7–13.
4. Schwarz F, Baumann P, Manthey J, et al. The effect of aortic valve replacement on survival. *Circulation*. 1982;66:1105–10.
5. Ross J Jr, Braunwald E. Aortic stenosis. *Circulation*. 1968;38 1 Suppl.:61–7.
6. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *G Ital Cardiol (2006)*. 2013;14:167–214.
7. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014.
8. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med*. 2011;364:2187–98.
9. Kolh P, Kerzmann A, Honore C, et al. Aortic valve surgery in octogenarians: predictive factors for operative and long-term results. *Eur J Cardiothorac Surg*. 2007;31:600–6.
10. Litmathe J, Feindt P, Kurt M, et al. Aortic valve replacement in octogenarians: outcome and predictors of complications. *Hellenic J Cardiol: HJC=Hellenike kardiologike epitheorese*. 2011;52:211–5.
11. Dell'Amore A, Aquino TM, Pagliaro M, et al. Aortic valve replacement with and without combined coronary bypass grafts in very elderly patients: early and long-term results. *Eur J Cardiothorac Surg*. 2012;41:491–8.
12. Di Eusanio M, Fortuna D, Cristell D, et al. Contemporary outcomes of conventional aortic valve replacement in 638 octogenarians: insights from an Italian Regional Cardiac Surgery Registry (RERIC). *Eur J Cardiothorac Surg*. 2012;41:1247–52, discussion 52–3.
13. Chiappini B, Camurri N, Loforte A, et al. Outcome after aortic valve replacement in octogenarians. *Ann Thorac Surg*. 2004;78:85–9.
14. Gehlot A, Mullany CJ, Ilstrup D, et al. Aortic valve replacement in patients aged eighty years and older: early and long-term results. *J Thorac Cardiovasc Surg*. 1996;111:1026–36.
15. Saxena A, Poh CL, Dinh DT, et al. Early and late outcomes after isolated aortic valve replacement in octogenarians: an Australasian Society of Cardiac and Thoracic Surgeons Cardiac Surgery Database Study. *Eur J Cardiothorac Surg*. 2012;41:63–8.
16. Yamane K, Hirose H, Youdelman BA, et al. Conventional aortic valve replacement for elderly patients in the current era. *Circ J*. 2011;75:2692–8.
17. Molstad P, Veel T, Rynning S. Long-term survival after aortic valve replacement in octogenarians and high-risk subgroups. *Eur J Cardiothorac Surg*. 2012;42:934–40.
18. Barili F, Pacini D, Capo A, et al. Does EuroSCORE II perform better than its original versions? A multicentre validation study. *Eur Heart J*. 2013;34:22–9.
19. Ghazy T, Kappert U, Ouda A, et al. A question of clinical reliability: observed versus EuroSCORE-predicted mortality after aortic valve replacement. *J Heart Valve Dis*. 2010;19:16–20.
20. Nashef SA, Roques F, Sharples LD, et al. EuroSCORE II. *Eur J Cardiothorac Surg*. 2012;41:734–44, discussion 44–5.
21. O'Brien SM, Shahian DM, Filardo G, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2 – isolated valve surgery. *Ann Thorac Surg*. 2009;88 1 Suppl.:S23–42.
22. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*. 1988;44:837–45.
23. Elayda MA, Hall RJ, Reul RM, et al. Aortic valve replacement in patients 80 years and older. Operative risks and long-term results. *Circulation*. 1993;88 5 Pt 2:II11–6.
24. Prêtre R, Turina MI. Cardiac valve surgery in the octogenarian. *Heart (British Cardiac Society)*. 2000;83:116–21.
25. Bloomstein LZ, Gielchinsky I, Bernstein AD, et al. Aortic valve replacement in geriatric patients: determinants of in-hospital mortality. *Ann Thorac Surg*. 2001;71:597–600.
26. Leontyev S, Walther T, Borger MA, et al. Aortic valve replacement in octogenarians: utility of risk stratification with EuroSCORE. *Ann Thorac Surg*. 2009;87:1440–5.
27. Basraon J, Chandrashekar YS, John R, et al. Comparison of risk scores to estimate perioperative mortality in aortic valve replacement surgery. *Ann Thorac Surg*. 2011;92:535–40.
28. Mack MJ. Risk scores for predicting outcomes in valvular heart disease: how useful? *Curr Cardiol Rep*. 2011;13:107–12.
29. Barili F, Pacini D, Capo A, et al. Reliability of new scores in predicting perioperative mortality after isolated aortic valve surgery: a comparison with the society of thoracic surgeons score and logistic EuroSCORE. *Ann Thorac Surg*. 2013;95:1539–44.
30. Iung B, Vahanian A. Towards improved risk scores: the quest for the grail continues. *Eur Heart J*. 2013;34:10–2.

31. Lebreton G, Merle S, Inamo J, et al. Limitations in the inter-observer reliability of EuroSCORE: what should change in EuroSCORE II? *Eur J Cardiothorac Surg.* 2011;40:1304–8.
32. lung B, Cachier A, Baron G, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? *Eur Heart J.* 2005;26:2714–20.
33. George I, Yerebakan H, Kalesan B, et al. TCT-758 Age alone should not preclude surgery: contemporary outcomes after aortic valve replacement in nonagenarians. *J Thorac Cardiovasc Surg.* 2014;148, 1360-9.e1.
34. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med.* 2010;363:1597–607.
35. Mistiaen WP, Van Cauwelaert P, Muylaert P, et al. Determinants of survival after aortic valve replacement as treatment for symptomatic aortic valve disease in the elderly. *J Heart Valve Dis.* 2001;10:354–60.
36. Ferrari E, Tozzi P, Hurni M, et al. Primary isolated aortic valve surgery in octogenarians. *Eur J Cardiothorac Surg.* 2010;38:128–33.